Literature DB >> 17704973

[New developments in hypericum extracts: data on efficacy and interactions].

Karin Kraft1.   

Abstract

The recent clinical studies on hypericum extract support the present indications for its use in mild to moderate depression and depressive episodes. The effectiveness is superior to placebo and comparable with synthetic antidepressive drugs. The rate of unwanted events is explicitly lower and their severity in general only mild. A further indication for hypericum could be somatoform disorders, but further clinical studies are recommended. The main compound responsible for interactions is presumably hyperforin, but further ingredients could contribute according to the specific composition of the particular extract.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704973     DOI: 10.1007/s10354-007-0439-1

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  27 in total

1.  Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy?

Authors:  P E Beattie; R S Dawe; N J Traynor; J A Woods; J Ferguson; S H Ibbotson
Journal:  Br J Dermatol       Date:  2005-12       Impact factor: 9.302

Review 2.  Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.

Authors:  Mario Wurglics; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Herb-drug interactions in oncology: focus on mechanisms of induction.

Authors:  Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2006 Jul-Aug

Review 4.  St John's wort for depression.

Authors:  K Linde; C D Mulrow; M Berner; M Egger
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 5.  Safety of St. John's Wort extract compared to synthetic antidepressants.

Authors:  V Schulz
Journal:  Phytomedicine       Date:  2005-11-02       Impact factor: 5.340

6.  Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial.

Authors:  Thomas Müller; Marcus Mannel; Harald Murck; Volker W Rahlfs
Journal:  Psychosom Med       Date:  2004 Jul-Aug       Impact factor: 4.312

7.  Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study.

Authors:  M Gastpar; A Singer; K Zeller
Journal:  Pharmacopsychiatry       Date:  2006-03       Impact factor: 5.788

8.  Antidepressant use in children and adolescents in Germany.

Authors:  Jörg M Fegert; M Kölch; Julie Magno Zito; Gerd Glaeske; Katrin Janhsen
Journal:  J Child Adolesc Psychopharmacol       Date:  2006 Feb-Apr       Impact factor: 2.576

Review 9.  Hyperforin in St. John's wort drug interactions.

Authors:  Rajanikanth Madabushi; Bruno Frank; Bernd Drewelow; Hartmut Derendorf; Veronika Butterweck
Journal:  Eur J Clin Pharmacol       Date:  2006-02-14       Impact factor: 2.953

10.  Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].

Authors:  Siegfried Kasper; Ion-George Anghelescu; Armin Szegedi; Angelika Dienel; Meinhard Kieser
Journal:  BMC Med       Date:  2006-06-23       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.